Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system

A novel gene therapy approach

Gianvito Martino, Pietro L. Poliani, Roberto Furlan, Peggy Marconi, Joseph C. Glorioso, Luciano Adorini, Giancarlo Comi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Pro-inflammatory cytokines play a crucial role in the regulatory and effector phase of the immune-mediated mechanism sustaining multiple sclerosis pathogenesis (MS) thus supporting the use of anti-inflammatory cytokines as a therapeutic option. Systemic administration of cytokines shows, however, limited therapeutic efficacy and undesirable/unpredictable side-effects. We have developed a non-toxic system to deliver cytokines within the central nervous system (CNS) based on the intrathecal (i.c.) administration of non- replicative herpes simplex (HSV) type-1-derived viral vectors engineered with heterologous cytokine genes. Compared to controls, mice affected by experimental autoimmune encephalomyelitis (EAE) and i.c. injected with an HSV-1-derived vector containing the gene of the anti-inflammatory cytokine IL-4 showed a significant amelioration of clinical and pathological EAE signs. A decreased mRNA expression of the monocyte chemoattractant protein-1 (MCP-1) by mononuclear CNS-infiltrating cells was also observed. Peripheral T cells from IL-4-treated mice were not affected both in their antigen-specific proliferative response and in the cytokine secretion pattern. Our results indicate that CNS cytokine delivery with HSV-1-derived vectors is a feasible therapeutic strategy and might represent an alternative approach for the treatment of immune-mediated demyelinating diseases. Advantages of this approach over systemic cytokine administration are the high cytokine level reached within the CNS and the absence of side-effects on the peripheral immune system. The short-lasting cytokine production in the CNS after a single vector administration (4 weeks) is the limiting factor of this novel technology which, although promising, has to be improved. (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)184-190
Number of pages7
JournalJournal of Neuroimmunology
Volume107
Issue number2
DOIs
Publication statusPublished - Jul 24 2000

Fingerprint

Demyelinating Diseases
Genetic Therapy
Central Nervous System
Cytokines
Human Herpesvirus 1
Therapeutics
Autoimmune Experimental Encephalomyelitis
Interleukin-4
Anti-Inflammatory Agents
Herpes Simplex
Chemokine CCL2
Genes
Multiple Sclerosis
Immune System
Technology
T-Lymphocytes
Antigens
Messenger RNA

Keywords

  • Cytokines
  • Experimental autoimmune encephalomyelitis
  • Gene therapy
  • Herpes simplex type-1- derived viral vectors
  • Inflammation
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Clinical Neurology
  • Neurology

Cite this

Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system : A novel gene therapy approach. / Martino, Gianvito; Poliani, Pietro L.; Furlan, Roberto; Marconi, Peggy; Glorioso, Joseph C.; Adorini, Luciano; Comi, Giancarlo.

In: Journal of Neuroimmunology, Vol. 107, No. 2, 24.07.2000, p. 184-190.

Research output: Contribution to journalArticle

@article{777cf2c764454b4e8928054d6d4c4b20,
title = "Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: A novel gene therapy approach",
abstract = "Pro-inflammatory cytokines play a crucial role in the regulatory and effector phase of the immune-mediated mechanism sustaining multiple sclerosis pathogenesis (MS) thus supporting the use of anti-inflammatory cytokines as a therapeutic option. Systemic administration of cytokines shows, however, limited therapeutic efficacy and undesirable/unpredictable side-effects. We have developed a non-toxic system to deliver cytokines within the central nervous system (CNS) based on the intrathecal (i.c.) administration of non- replicative herpes simplex (HSV) type-1-derived viral vectors engineered with heterologous cytokine genes. Compared to controls, mice affected by experimental autoimmune encephalomyelitis (EAE) and i.c. injected with an HSV-1-derived vector containing the gene of the anti-inflammatory cytokine IL-4 showed a significant amelioration of clinical and pathological EAE signs. A decreased mRNA expression of the monocyte chemoattractant protein-1 (MCP-1) by mononuclear CNS-infiltrating cells was also observed. Peripheral T cells from IL-4-treated mice were not affected both in their antigen-specific proliferative response and in the cytokine secretion pattern. Our results indicate that CNS cytokine delivery with HSV-1-derived vectors is a feasible therapeutic strategy and might represent an alternative approach for the treatment of immune-mediated demyelinating diseases. Advantages of this approach over systemic cytokine administration are the high cytokine level reached within the CNS and the absence of side-effects on the peripheral immune system. The short-lasting cytokine production in the CNS after a single vector administration (4 weeks) is the limiting factor of this novel technology which, although promising, has to be improved. (C) 2000 Elsevier Science B.V.",
keywords = "Cytokines, Experimental autoimmune encephalomyelitis, Gene therapy, Herpes simplex type-1- derived viral vectors, Inflammation, Multiple sclerosis",
author = "Gianvito Martino and Poliani, {Pietro L.} and Roberto Furlan and Peggy Marconi and Glorioso, {Joseph C.} and Luciano Adorini and Giancarlo Comi",
year = "2000",
month = "7",
day = "24",
doi = "10.1016/S0165-5728(00)00236-8",
language = "English",
volume = "107",
pages = "184--190",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "2",

}

TY - JOUR

T1 - Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system

T2 - A novel gene therapy approach

AU - Martino, Gianvito

AU - Poliani, Pietro L.

AU - Furlan, Roberto

AU - Marconi, Peggy

AU - Glorioso, Joseph C.

AU - Adorini, Luciano

AU - Comi, Giancarlo

PY - 2000/7/24

Y1 - 2000/7/24

N2 - Pro-inflammatory cytokines play a crucial role in the regulatory and effector phase of the immune-mediated mechanism sustaining multiple sclerosis pathogenesis (MS) thus supporting the use of anti-inflammatory cytokines as a therapeutic option. Systemic administration of cytokines shows, however, limited therapeutic efficacy and undesirable/unpredictable side-effects. We have developed a non-toxic system to deliver cytokines within the central nervous system (CNS) based on the intrathecal (i.c.) administration of non- replicative herpes simplex (HSV) type-1-derived viral vectors engineered with heterologous cytokine genes. Compared to controls, mice affected by experimental autoimmune encephalomyelitis (EAE) and i.c. injected with an HSV-1-derived vector containing the gene of the anti-inflammatory cytokine IL-4 showed a significant amelioration of clinical and pathological EAE signs. A decreased mRNA expression of the monocyte chemoattractant protein-1 (MCP-1) by mononuclear CNS-infiltrating cells was also observed. Peripheral T cells from IL-4-treated mice were not affected both in their antigen-specific proliferative response and in the cytokine secretion pattern. Our results indicate that CNS cytokine delivery with HSV-1-derived vectors is a feasible therapeutic strategy and might represent an alternative approach for the treatment of immune-mediated demyelinating diseases. Advantages of this approach over systemic cytokine administration are the high cytokine level reached within the CNS and the absence of side-effects on the peripheral immune system. The short-lasting cytokine production in the CNS after a single vector administration (4 weeks) is the limiting factor of this novel technology which, although promising, has to be improved. (C) 2000 Elsevier Science B.V.

AB - Pro-inflammatory cytokines play a crucial role in the regulatory and effector phase of the immune-mediated mechanism sustaining multiple sclerosis pathogenesis (MS) thus supporting the use of anti-inflammatory cytokines as a therapeutic option. Systemic administration of cytokines shows, however, limited therapeutic efficacy and undesirable/unpredictable side-effects. We have developed a non-toxic system to deliver cytokines within the central nervous system (CNS) based on the intrathecal (i.c.) administration of non- replicative herpes simplex (HSV) type-1-derived viral vectors engineered with heterologous cytokine genes. Compared to controls, mice affected by experimental autoimmune encephalomyelitis (EAE) and i.c. injected with an HSV-1-derived vector containing the gene of the anti-inflammatory cytokine IL-4 showed a significant amelioration of clinical and pathological EAE signs. A decreased mRNA expression of the monocyte chemoattractant protein-1 (MCP-1) by mononuclear CNS-infiltrating cells was also observed. Peripheral T cells from IL-4-treated mice were not affected both in their antigen-specific proliferative response and in the cytokine secretion pattern. Our results indicate that CNS cytokine delivery with HSV-1-derived vectors is a feasible therapeutic strategy and might represent an alternative approach for the treatment of immune-mediated demyelinating diseases. Advantages of this approach over systemic cytokine administration are the high cytokine level reached within the CNS and the absence of side-effects on the peripheral immune system. The short-lasting cytokine production in the CNS after a single vector administration (4 weeks) is the limiting factor of this novel technology which, although promising, has to be improved. (C) 2000 Elsevier Science B.V.

KW - Cytokines

KW - Experimental autoimmune encephalomyelitis

KW - Gene therapy

KW - Herpes simplex type-1- derived viral vectors

KW - Inflammation

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0034710341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034710341&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(00)00236-8

DO - 10.1016/S0165-5728(00)00236-8

M3 - Article

VL - 107

SP - 184

EP - 190

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 2

ER -